byUniversity of Sheffield

Credit: Pixabay/CC0 Public Domain

A drug candidate found to protect nerve cells damaged by motor neuron disease (MND), could offer new hope to people living with the devastating condition.

Researchers at the University of Sheffield's Institute for Translational Neuroscience (SITraN) discovered and developed M102, a new medicine that has powerful protective effects on thenerve cellsthat are damaged by the neurodegenerative disease that currently has no cure.

Inpreclinical studies, M102 sloweddisease progressionand preserved muscle function in mice with MND, improving movement, gait, and nerve function.

Importantly, it also protectedmotor neuronsgrown in the laboratory from damage caused by MND patient cells known as astrocytes. These are cells in the nervous system which normally support and protect motor neurons.

The findings,published in the journalMolecular Neurodegeneration, suggest M102 could significantly extend length and quality of life for people living with MND.

Motor neuron disease (MND), also known asamyotrophic lateral sclerosis(ALS), is a progressive and life-shortening condition that affects the nerve cells in the brain andspinal cordthat control movement (motor neurons).

MND causes the motor neurons to gradually stop sending messages to muscles, leading to progressive muscle weakness, muscle wasting, and stiffness. This can affect a person's ability to walk, talk, swallow, and breathe. Most people with MND die within two to five years from the onset of symptoms.

Professor Dame Pamela Shaw, director of SITraN and lead investigator of the study, said, "MND is one of the cruelest diseases, robbing people of their mobility and independence often at an alarming speed. We are now at a point where scientific understanding is finally catching up. Our discovery of M102 gives real hope that we can substantially slow the progression of this disease.

"The preclinical studies not only showed improvement in movement, gait, and nerve function in mouse models, but it also protected motor neurons grown in the laboratory from damage caused by MND patient cells."

Unlike mostcurrent treatmentsthat focus on a single biological pathway, M102 works in a dual-action, activating two major protective systems inside cells—called NRF2 and HSF1. Together, these systems help nerve cells combat stress, reduce inflammation, improveenergy generationand clear away damaged proteins—all of which are known to contribute to motor neuron injury in MND.

The groundbreaking research is a collaboration between the University of Sheffield and Aclipse Therapeutics, a biotech company based in the United States.

Dr. Richard Mead, senior lecturer in translational neuroscience at SITraN and lead co-author of the study, said, "Turning scientific discovery into real treatments takes teamwork—bringing together researchers, clinicians, industry partners, and investors. Our collaboration with Aclipse Therapeutics has built that essential bridge between the research laboratory and the clinic.

"We're now ready to take the next crucial step: testing M102 in people with MND and moving closer to a treatment that can truly make a difference."

The Sheffield research team has confirmed M102's safety and ability to protect motor neurons in animal models. The next steps are to enter clinical trials in humans once funding has been secured.

More information: Amy F. Keerie et al, M102 activates both NRF2 and HSF1 transcription factor pathways and is neuroprotective in cell and animal models of amyotrophic lateral sclerosis, Molecular Neurodegeneration (2025). DOI: 10.1186/s13024-025-00908-y Journal information: Molecular Neurodegeneration

Provided by University of Sheffield